

1 Supplemental data

2 Methods

3 Immunohistochemistry

4 Staining was performed manually or using the Ventana BenchMark Ultra automated IHC/ISH
5 slide staining system (Ventana Medical Systems Inc., Tucson, USA) (suppl. table 1a). The
6 cytoplasmic expression of TFF3 and MUCL3 was evaluated using the immunoreactivity scoring
7 system (IRS) based on staining intensity (0: negative, 1: mild, 2: moderate, 3: intense) and the
8 percentage of stained cells (0: no positive cells, 1: <10% positive cells, 2: 10-50% positive cells,
9 3: 51-80% positive cells, 4: >80% positive cells). The final score (0-12) was found by multiplying
10 the positive cells proportion score (0-4) and the staining intensity score (0-3). The mean value
11 of Ki67 proliferation rate of five randomly selected high power (40x) fields (HPFs) was
12 calculated using the percentage of stained cells.

13 DNA/ RNA Isolation from FFPE samples

14 For genomic DNA or total RNA Isolation, 5-8 8- μ m-thick tissue sections were prepared, and
15 lesions were dissected manually or by laser-capture microdissection (LMD), depending on
16 their size to ensure adequate cellularity (>80%) for subsequent molecular analysis. For LMD,
17 cresyl violet staining was done before using the Palm Microbeam System (Carl Zeiss,
18 Oberkochen, Germany) according to the manufacturer's instructions. In some samples
19 containing larger lesions, manual microdissection was used, as previously described.[1] The
20 obtained cell clusters were isolated using the QIAamp DNA micro Kit or the GeneRead FFPE
21 DNA Kit for DNA and the RNeasy FFPE Kit for RNA (all from Qiagen, Hilden, Germany) following
22 the manufacturer's instructions. The genomic DNA quality control was performed by
23 quantitative PCR using the Power SYBR™ Green PCR Master Mix on a StepOnePlus™ Real-Time
24 PCR System. Quantification was performed with a self-designed primer assay (HML-2 for: 5'
25 AAACGCCAATCCTGAGTGTC-3'; HML-2 rev: 5' CATAGCTCCTCCGATTCAT-3'). These primers
26 are complementary to long terminal repeats (LTRs) of the HML 2 human endogenous
27 retroviruses and have a length of about 115 bp.

1 Targeted NGS

2 A PDAC-Panel with two primer pools was created by the Ion AmpliSeq™ Designer (v5.6,
3 ThermoFisher Scientific, Dreieich, Germany). The panel consists of 217 amplicons of 21 genes
4 covering hot-spot mutational sites of 18 and the whole coding sequence of 3 (*ARID1A*, *TP53*
5 and *RNF43*) additional genes relevant for PDAC (suppl. table 2). Barcoded libraries from gDNA
6 (up to 10 ng per pool) were prepared using the Ion AmpliSeq Library kit 2.0 with Ion Xpress™
7 Barcode adapters. The Ion library TaqMan™ Quantitation Kit was used for quantification of
8 the libraries. The libraries were pooled and amplified in an emulsion PCR reaction using the
9 Ion 520™ & Ion 530™ Kit-OT2. The resulting Ion Sphere particles (ISPs) were loaded on a 520™
10 or 530™ Chip and sequenced on the Ion S5™ system (all reagents from ThermoFisher).

11 The results of the next generation sequencing from the Ion S5™ system were aligned to the
12 human reference genome (GRCh37/hg19) using the S5 Ion Torrent Server VM (ThermoFisher).
13 The Ion Reporter software (Version 5.12.0.0) was used for variant calling and annotations of
14 the DNA panel sequencing. The parameters for variant calling were set equal for all samples.
15 Following thresholds were defined: 3% allele frequency with a minimum coverage of 500 and
16 a Phred Score of ≥ 30 . Detected variants were validated using the Integrative Genomics Viewer
17 (IGV), ClinVar database from National Institutes of Health (NIH) and University of California
18 Santa Cruz (UCSC) Genome Browser. Variants not present in the above mentioned databases
19 were classified according to the American College of Medical Genetics and Genomics (ACMG)
20 guidelines using the ACMG database (varsome.com; v7.3.7).[2]

21 Fusion transcript analysis

22 50 ng of isolated RNA were used for cDNA synthesis by QuantiTect Reverse Transcription Kit
23 (Qiagen) and were subsequently subjected to library preparation using the Oncomine
24 Comprehensive Assay Plus RNA (ThermoFisher) targeting over 1,300 isoforms of 49 tumor
25 driver genes including approximately 200 known *BRAF* fusion transcripts. NGS was performed
26 (as described above) and data analysis was done using the Oncomine Comprehensive Plus
27 w2.1 - Fusion workflow implemented within the IonReporter Software package (V5.18;
28 ThermoFisher).

29 Isolation of epithelial cells from the main pancreatic duct and from peripheral (branch) ducts

1 Specimens were obtained fresh from the operating theater and immediately subjected to
2 gross examination. The main pancreatic duct was probed, and the specimen dissected by a
3 pathologist along the probe. The main duct was then carefully dissected with a scissor and
4 then fixed in 10% buffered formalin and embedded in paraffin. Peripheral tissue blocks were
5 prepared, and branch-ducts were isolated by LMD, as described above. DNA extraction was
6 performed as described above.

7 **Generation of β -cells**

8 β -cell populations from FFPE tissue were generated from 50- μ m-thick sections. Tissue sections
9 were dewaxed with xylol and rehydrated in descending ethanol concentrations. Antigen
10 retrieval was done at 80°C for one hour in a pressure cooker before tissue was digested with
11 1% (w/v) collagenase Ia (Sigma, Steinheim, Germany) and 1%(w/v) dispase (Gibco, Grand
12 Island, USA) for 45 min at 37°C to obtain single cells. The cell suspension was subsequently
13 filtered (30 μ m mesh) and the cells were collected by centrifugation. Single cells were stained
14 Insulin (Abcam, Cambridge, UK; 1:200). The stained cells were sorted with a BD FACS Aria™
15 III System. DNA was isolated from the sorted cells as described above.

16 **Transcriptome analysis**

17 After total RNA isolation, the samples were shipped to Macrogen (Seoul, Korea) for
18 sequencing. Libraries from total RNA were prepared using the Illumina TruSeq™ Stranded
19 mRNA Library Prep kit and sequenced with 2 x 100 bp on the Illumina NovaSeq 6000 (Illumina
20 Inc, San Diego, USA). The raw data processing of the transcriptome data was performed by
21 Macrogen. Briefly, adapter and low-quality base trimming was carried out with Trimmomatic
22 (v0.38).[3] Trimmed reads were mapped against the GRCh38/hg38 human reference genome
23 using the Bowtie2 (v2.3.4.1) aligner.[4] Afterwards, the aligned reads were assembled with
24 Cufflinks (v2.2.1).[5] After assembly the abundance of gene was calculated in read counts per
25 gene. Before differential gene expression analysis lowly expressed genes were filtered from
26 the data set. Therefore, genes which showed a lower read count as 0.5 transcripts per million
27 reads and were missing in more than one sample per group were excluded from further
28 analysis. The filtered raw count matrix was normalized and batch-corrected using the DESeq2
29 package (v3.14).[6] Finally, differentially expressed genes were calculated pairwise and
30 defined as followed \log_2 fold change of < -1 and > 1 , respectively, and the significance level of

1 the adjusted p-value was set to < 0.05. PCA, heatmap and expression plots were calculated
2 based on the variance stabilizing transformation output of DESeq2

3 **Pathway analysis**

4 Gene set enrichment analysis

5 For methylation data, enrichment of KEGG terms was estimated for all differentially
6 methylated probes (DMP) in a pair-wise manner. DMPs were defined as displaying a beta
7 value change of 0.4 and an adjusted p-value < 0.05. Gene set enrichment was calculated with
8 the gometh function of the missMethyl package (v.1.26.1).[7]

9 The single sample Gene Set Enrichment Analysis (ssGSEA) was performed only for RNA seq
10 derived data. Briefly, the normalized enrichment scores (NES) were calculated on the variance
11 stabilized transformation data with the GSVA package (v.1.40.1).[8] Differentially activated
12 gene sets were calculated between the different precursor lesions as described by Larsen *et*
13 *al.* with a p-value of < 0.05.[9]

14 VIPER analysis

15 The activation of transcription factors was calculated with the VIPER algorithm (v1.26.0).[9]
16 For the analysis, the paad regulon was taken from the arcane.networks package (1.18.0).
17 Activated transcription factors were defined as displaying a p-value < 0.005 and a NES score
18 of >3 or >-3.

19 **Statistical analysis**

20 Statistical analysis was performed using the GraphPad Prism 8 software (GraphPad Software
21 Inc., San Diego, USA) or R v. 3.6.0 (R Core Team 2018). Statistical significance in
22 immunohistochemistry was determined by Kruskal-Wallis test with Dunn's multiple
23 comparison test. Results are presented as means \pm standard error of the mean (SEM). P values
24 less than 0.05 were considered statistically significant (* p< 0.05; ** p < 0.01; *** p<0.001).

1 References

- 2 1 Schlitter AM, Born D, Bettstetter M, *et al.* Intraductal papillary neoplasms of the bile
3 duct: Stepwise progression to carcinoma involves common molecular pathways. *Mod*
4 *Pathol* 2014;27:73–86.
- 5 2 Richards S, Aziz N, Bale S, *et al.* Standards and guidelines for the interpretation of
6 sequence variants: a joint consensus recommendation of the American College of
7 Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet*
8 *Med* 2015;17:405–24.
- 9 3 Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence
10 data. *Bioinformatics*. 2014;30:2114-2120.
- 11 4 Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nat Methods*
12 2012;9:357-9.
- 13 5 Li H, Handsaker B, Wysoker A, *et al.* The sequence alignment/map format and
14 SAMtools. *Bioinformatics* 2009;25:2078-9.
- 15 6 Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for
16 RNA-seq data with DESeq2. *Genome Biol* 2014;15:550.
- 17 7 Phipson B, Maksimovic J, Oshlack A. missMethyl: an R package for analyzing data from
18 Illumina's HumanMethylation450 platform. *Bioinformatics* 2016;32:286-8.
- 19 8 Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray
20 and RNA-seq data. *BMC Bioinformatics* 2013;14:7.
- 21 9 Larsen BM, Kannan M, Langer LF, *et al.* A pan-cancer organoid platform for precision
22 medicine. *Cell Rep* 2021;36:109429.
- 23 10 Alvarez MJ, Shen Y, Giorgi FM, *et al.* Functional characterization of somatic mutations
24 in cancer using network-based inference of protein activity. *Nat Genet* 2016;48:838-
25 47.

26

1 **Supplementary tables**2 **Supplementary table 1a: Antibodies and protocols for immunohistochemistry.**

Antibody	Type	Dilution	Antigen Demasking	Source
Anti-MUC1	Mo Mono	1:100	CC1	Biocare
Anti-MUC2	Mo Mono	1:100	CC1	Dako
Anti-MUC5AC	Mo Mono	1:1000	CC1	Chemicon
Anti-CDX2	Mo Mono	1:40	CC1	BioGenex
Anti-MIB1	Mo Mono	1:100	CC1	Dako
Anti-TFF3	Rb Mono	1:2000	EDTA buffer pH 9	Abcam
Anti-MUCL3	Rb Poly	1:500	Citrate buffer pH 6	LSBio

3 *Rb: rabbit. Mo: mouse Mono: monoclonal. Poly: polyclonal. CC1: Cell Conditioning 1 (Ventana Medical System, Tucson, AZ,
4 USA).

5 **Supplementary table 1b: Tissue collective used for Ki67, TFF3 and anti-MUC13 staining.**

Type of lesion	Number of lesions
PanIN	31
Low grade	26
High grade	5
Gastric IPMN	28
Low grade	20
High grade	8
Intestinal IPMN	20
Low grade	9
High grade	11
PDAC	24

6

1 Supplementary table 2: Genes and amplicons in targeted NGS.

Gene Symbol	Chr	Ion AmpliSeq Fwd Primer (5'-3')	Ion AmpliSeq Rev Primer (5'-3')	Amplicon ID
ALK	chr2	TCTCTCGGAGGAAGGACTTGAG	GCCAGACTCAGCTCAGTTAAT	CHP2_ALK_1
ALK	chr2	ACAGGGTACCAGGAGATGATGTAAG	GGAAGAGTGGCCAAGATTGGA	CHP2_ALK_2
APC	chr5	GAGAGAACGCGGAATTGGTCTA	GTATGAATGGCTGACACTTCTCCA	CHP2_APC_1
APC	chr5	AGCACTGATGATAAACACCTCAAGTT	ATCTTCTTGACACAAAGACTGGCT	CHP2_APC_2
APC	chr5	TTCAATATCATCTTTGTCATCAGCTGAA	TTTGGTTCTAGGGTGTGTGAC	CHP2_APC_3
APC	chr5	GCAGACTGCAGGGTTCTAGTT	GTGAAGTACAGAAAGTACATCTGCT	CHP2_APC_4
APC	chr5	AGCCCCAGTGTCTCCAGATA	CCCTTGAAGTGCAGCATTACT	CHP2_APC_5
APC	chr5	AGAGGGTCCAGGTTCTCCA	TCATTTCTGAACTGGAGGCATT	CHP2_APC_6
APC	chr5	ATGAAACAGAATCAGAGCAGCCTAAA	CGTGATGACTTTGTTGGCATGG	CHP2_APC_7
ARID1A	chr1	CAAAATGAACAACAAGGCAGATGGG	TCAGAGACTATCTAGTCCGGTGTCT	ARID1A_10.112972
ARID1A	chr1	CAGCTAACTTACTGGACTTGAGAATTTTT	GAGTCAAGACAAAAATCACTACCTTGG	ARID1A_10.135473
ARID1A	chr1	CATGATGGGAACTGGACCTCCTTA	TTAGCTGTGATGTGACTCTGAAGAAAT	ARID1A_10.143283
ARID1A	chr1	CCCCAGCTACGGCTTC	CCCCCGTAGGGCTCCA	ARID1A_1.1.15178
ARID1A	chr1	CCTAGGCCCGCCCTGA	GGCTCCGGCCGTAGGGT	ARID1A_1.1.16654
ARID1A	chr1	CAGTCAAGAGACTTCTGAGACCCTTA	CAGATAACGGTCCACCCACATC	ARID1A_11.181180
ARID1A	chr1	CCGCTGGGAAAGGAGCTG	GCCTAGGGCCCGCTTC	ARID1A_1.1.20289
ARID1A	chr1	CTATGCCTCTATGTGTCTGTGAAG	GTACCACATGAAGCCAGTGAGTAC	ARID1A_11.248116
ARID1A	chr1	ACAACTCTACTACCCAACC	CTGCTGAGCGAAGGACGA	ARID1A_1.1.2481
ARID1A	chr1	CTCCAGAAATCCAGTTCTTCTACTACA	ATAGAGGTCCAGAGGTTTCTACC	ARID1A_11.279375
ARID1A	chr1	CTCAGCAGCGCTTCGGG	GGGCCGCGCCACTGTAGT	ARID1A_1.1.36612
ARID1A	chr1	CTCGGAGCTGAAGAAAGCCG	GCTCTCGGCCCGCTCT	ARID1A_1.1.38056
ARID1A	chr1	GAGCCGTCTGCCGTCG	GGAGTGTACTGGTGGTTGGG	ARID1A_1.1.42139
ARID1A	chr1	GGCCCCAGCAGAAGCTCTCAC	AGCCCGGAGTGCCACCTC	ARID1A_1.1.52554
ARID1A	chr1	GGCTGCCGGCTCCAAGC	GCTGGCGACGTGAGCA	ARID1A_1.1.54514
ARID1A	chr1	GGGATCATGGCCGCGCA	CCGGCGGCTGCCTTCAT	ARID1A_1.1.54590
ARID1A	chr1	TTATCTGGCCTTCACTGAGGAGAA	CTCACCTGAGTCAATCCACCAAT	ARID1A_11.550938
ARID1A	chr1	AGCCGGACTGAAGAAGCTCG	GGCCGCGGCTGAGTGAG	ARID1A_1.1.6484
ARID1A	chr1	CTCGCCCGGACCCCTCAG	GCCAGACAATGGCAGCTCC	ARID1A_1.2.19161
ARID1A	chr1	GGGTACCAGGGCTACCC	GGGCTCATGGGCGCTG	ARID1A_1.2.26067
ARID1A	chr1	GATATACCTCGACTCCTTTGGTTTGG	AGGGTCTTCTCCCGTTCAAT	ARID1A_12.293039
ARID1A	chr1	GCCAGCTCCTTGAAAAGCAGTATATC	GACCCATCCTTACCAGGAGAG	ARID1A_12.311881
ARID1A	chr1	AGACATCTTTCAGCTGTGATT	CACAGATCCTTGGCATATCCTGTTG	ARID1A_12.73402
ARID1A	chr1	CCGGCGGACATGGCCTC	CCTCCCACTCAGCTGTGTA	ARID1A_1.2.9363
ARID1A	chr1	CTCAACTTGTATCTGTCCACAGC	CTGCTCTGGCCTTACCTCATG	ARID1A_13.224100
ARID1A	chr1	CTCCTGCGTGTCTTTGTTATATTGG	TGGAGTCATGGAATCCGCTT	ARID1A_13.228066
ARID1A	chr1	GAGGAGACTTAAAGCCACCAACTC	CAAGGAGTCCCATGCACTTATCT	ARID1A_13.262576
ARID1A	chr1	GCCTTGTAGATCCTCTGCTAAGAAG	GCCCTGCATAGATCCTGATCC	ARID1A_13.286741
ARID1A	chr1	CTTAATGATGGAAGTACTCCACATTC	CAAGTCAAATAGCAATCAGATCAGTCA	ARID1A_14.234479
ARID1A	chr1	TGACTCAAACCTGGGTATCA	CATTTCACTGGCCCTGTCTTACG	ARID1A_14.440936
ARID1A	chr1	GACCACGACAGCACTATCCCTA	TCATGTTCCCTCAGGCCCTATT	ARID1A_15.209989
ARID1A	chr1	TCACCCTTGCCTTTCTACG	TCACTGTGCATAAGGACCTCCA	ARID1A_15.321878
ARID1A	chr1	CCAATTTTGTAGGACGGAGCCT	CACCGAGACCAGGCTTACTC	ARID1A_15.99688

ARID1A	chr1	CTAATCCTGTGTTCTTTGCCTCCT	TTTTCAAGGCGAACCTGCATG	ARID1A_16.147847
ARID1A	chr1	GGATGTATTCTCCTAGCCGCTAC	TTGGGTGGAGAACTGATTGCCATA	ARID1A_16.243588
ARID1A	chr1	AGCGTGCATACAGCACT	GGCAGTGGCAGGATAGGCA	ARID1A_18.122838
ARID1A	chr1	AACCGCACCTCTCCTAGC	TCCCGCGAATCATGGG	ARID1A_18.17117
ARID1A	chr1	CAGATGAAATGCTGCACACAGATC	GATACCTGAGGAATGTGATTCTGCAT	ARID1A_18.249269
ARID1A	chr1	CAGGTATCCAGCCCTGCTC	TGCTATGTGCGAGGCAGGT	ARID1A_18.260793
ARID1A	chr1	CCACTGCCACAGCTGCTAC	GCTGAGCAACCTCAGCTGAT	ARID1A_18.303487
ARID1A	chr1	AAGGCTCGTGGCCTTCCC	GTGCGGTTCTCCATTGGC	ARID1A_18.33212
ARID1A	chr1	CTGTGTCCACCAAGCATCTGG	GGCACGCTGTACATCTCC	ARID1A_18.457891
ARID1A	chr1	GCAAACATGCCACCACAAATGATG	TGTTCCGGTTCACGCCATGATAG	ARID1A_18.536845
ARID1A	chr1	GCCTTCCCCTCAGCAAGATGTATA	GGTCTCGGCCAACTGGAATG	ARID1A_18.584475
ARID1A	chr1	ACATAGCACCTGCCCTGT	GGGCAGATTAGGCAACCGAATG	ARID1A_18.63843
ARID1A	chr1	TGCTCAGCAAGGCACCATG	CGAGCCTTCGTGGTTGG	ARID1A_18.820768
ARID1A	chr1	TTGTCTCTGCCTTAGAATTACAAGCG	GCTGGGCAGCTTGTGCT	ARID1A_18.880618
ARID1A	chr1	AGACGACATGGAGGTTTATTCAGG	CCCAGGCACTGATACTCA	ARID1A_19.54023
ARID1A	chr1	ATCTTCAGAGTAGCTTCACTGATGGG	GTTGATGGTATCTAATGCCATGTG	ARID1A_19.79292
ARID1A	chr1	CAACATCCTGCTGTATGATGACAAC	GGCATGGAAGATATCTACAAGAGAGAAA	ARID1A_19.96133
ARID1A	chr1	ATCCTGGGAGGTTTCAGCAA	GAAGCTGGCTTGCCTTGC	ARID1A_20.1.247050
ARID1A	chr1	CCAGTTCAGAGAATAGTGAGGA	GCAGCAGGCCACTGTCAAA	ARID1A_20.1.351511
ARID1A	chr1	CCCTGGGAAGCATGTGACAAC	CTTGATGGCCTCTGAACCTTAGC	ARID1A_20.1.374770
ARID1A	chr1	CCTGTGCACTGGCGGAT	GGCCCTCCTGGTCTGTTG	ARID1A_20.1.397870
ARID1A	chr1	CGAAGCCTGTCAATTTGTGCCA	GTTAGTGGTGCCTGCTTCCG	ARID1A_20.1.400147
ARID1A	chr1	CTGTTCTTAGGCCACTTTTCTCC	CCCAGGATCCAGTAGCGTT	ARID1A_20.1.464959
ARID1A	chr1	GAGGAAGTAGTTGAAAATGATGAGGAGA	TCCACCACAAATGGATCATTCTTCTGTA	ARID1A_20.1.565326
ARID1A	chr1	GCAGCAAGTTTCCATTGGCATTAG	AGGCTTCGAATGGTATTGGACAC	ARID1A_20.1.612574
ARID1A	chr1	GCCTGATTGAGATCTTTGGCATTAAAA	ACTTCTCTTCTTCTTCTTCTTAGTTTA	ARID1A_20.1.637352
ARID1A	chr1	GGGCCCCACCTGATGGA	GTTCCGGTGGCTCTGTGC	ARID1A_20.1.733579
ARID1A	chr1	GTGGTGGACTGCTCAGATAAGCT	AGCTCTGTCTTGTCTCGAAGT	ARID1A_20.1.787955
ARID1A	chr1	ACCGGAACATCAAGATCCTAGAG	CCCTGGGTGTTGGACATC	ARID1A_20.1.90003
ARID1A	chr1	ATGGTGCCTTCTCAGT	CGGCAAGGCTGCTCTAG	ARID1A_20.2.152846
ARID1A	chr1	CAGTGCAGAAGGGCAGTATCG	CCGCATCATGTCCACACTAGTTG	ARID1A_20.2.222602
ARID1A	chr1	CCACTAATTATGAAAAGGAGGAGGAA	CCCGAGATGTTGGCGAGTGTA	ARID1A_20.2.247152
ARID1A	chr1	CCTTGCCGCCACACAGTT	CAACAGCCGTGATTCTGACA	ARID1A_20.2.313338
ARID1A	chr1	CTTGAGATGCTCCGGGAA	AGGGCAAACTGCCAGTGTA	ARID1A_20.2.409280
ARID1A	chr1	CTTCAGCTGAAGCCAGGAC	CGACCATAGTGTATACAATTCT	ARID1A_20.2.432258
ARID1A	chr1	AAACTCAGCATCCAGGACAACAAT	GCCAGGTTGGCCAGCAGTA	ARID1A_20.2.5295
ARID1A	chr1	ACCCAGGGCTGCTGCTCAT	TCTCCAAGCAGTCCCACCA	ARID1A_20.2.54967
ARID1A	chr1	GGCTGTTGGACATCTCGGT	GTTTTGCATAAATAAGGGCAACAGTC	ARID1A_20.2.603909
ARID1A	chr1	GGGCAGTTGGACCTATCTCCATAC	CTGAGTTTGTGAGGGTTCCAA	ARID1A_20.2.613243
ARID1A	chr1	TGGACGAGAACCCTCAGAGTTTAC	GCTGTCTGACTGGCAATCAAAA	ARID1A_20.2.760156
ARID1A	chr1	CATGGGCGGCTCTTATAC	TAGTAGCACTGTAAATTAAGTCCCA	ARID1A_2.198073
ARID1A	chr1	CTAACCCATACTCGCAGCAACA	TCACAATCACCATCTACCTGCTG	ARID1A_2.263887
ARID1A	chr1	GCCATCCAGTCCAATGGATCAG	CCTGCATGGTCTCGGGTAC	ARID1A_2.310812
ARID1A	chr1	AAACCTGTGTAAGTGGTTATATATTCAGT	CCATATGGCTGAGGTTCTCATCTTG	ARID1A_2.6808
ARID1A	chr1	AGTCCAGCAAACTGCCTATTC	ACCCAGAGTTAATTGGTCTTAAAGTG	ARID1A_3.115759

ARID1A	chr1	CAGCAAAGTCTCACCTCAG	GGGATGGCTGCTGGGAGTAT	ARID1A_3.189854
ARID1A	chr1	CAGCTCCACATCAGCAGTC	AGCCTGCTGGGAGAGCGT	ARID1A_3.203145
ARID1A	chr1	CAGGCTCAGTCTCCTTACCA	GCAGGAGGCAGGGATATCTT	ARID1A_3.210697
ARID1A	chr1	TGCTTCTATACTCATCATCAGTGCAT	CTTTGCTGGTTGTAATATGGAGTCTG	ARID1A_3.663071
ARID1A	chr1	TTTTCTTTCTACAGATTCCTCCTT	CTGCTGCTGATACGAAGGTTG	ARID1A_3.701387
ARID1A	chr1	AGCAGCAGCCACAGTCTCAA	TGAGCCTGTGGCTGTGAGTA	ARID1A_3.77267
ARID1A	chr1	CCATCACAGCTTTTGTTTTCTTGTGTAG	ACCTTCAGAAGGTGCAGAAATACT	ARID1A_4.173246
ARID1A	chr1	CTGGCCTTACATAATACTTTTCGC	GATGCCTGAGACCCAAATGAATC	ARID1A_4.215850
ARID1A	chr1	GAGGGCAAGAAGATATGAACCTGAG	AGGTCAAATTAGCTAAACTTCCAACCA	ARID1A_4.255932
ARID1A	chr1	GAGTCTGGAGTGAGCACATC	CGAGAGTGGTCTGAGCGA	ARID1A_5.220317
ARID1A	chr1	AGAATCTTCTGCCTAATATACTAATCCATG	AGGAGACTGAGCTGGATTACTCT	ARID1A_5.34011
ARID1A	chr1	AGTCTCTTTCTCTCCTACACT	CAGTCACTTTCCCTCTCCCTAA	ARID1A_5.70816
ARID1A	chr1	GATATGCTTATGTTGTTCTTGTCTGGA	CACTCAAATGTCTGCCCTAGCTC	ARID1A_6.227771
ARID1A	chr1	AGCCATTTCTAGCTCTGAATTAACCTCC	TCGATCTTGGGCAATGCTTGAT	ARID1A_6.45476
ARID1A	chr1	CAGCCTTATCTCCGCGTCAG	ACTGTTTTCTCTCACCCTGAT	ARID1A_7.149596
ARID1A	chr1	CAGGATAAGGATGGAGAGCATTGTTC	TGTGTATCTGTCTCCGGAA	ARID1A_7.152412
ARID1A	chr1	CATGGCCAATATGCCACCTCA	ATAATACATTTTCTTGACTGACACCCT	ARID1A_8.210031
ARID1A	chr1	CCAATGCCAACTACCCAGTG	GGCCATGTTAGGGCCATAAGG	ARID1A_8.229785
ARID1A	chr1	GTTGCTAGTGAGTGACTAACCAAGTC	GGCTGTCCATGCATTTGACCTC	ARID1A_8.517555
ARID1A	chr1	AGGATGAGTCACGCCTCCATG	GGCCTTACCTGTTTTGGATAGAGTTG	ARID1A_8.91537
ARID1A	chr1	AGCACTATTTGGCTCCAGTTCAAATC	GGTTGATCATGCCAGCCATACTATTA	ARID1A_9.65769
BRAF	chr7	CATACTTACCATGCCACTTTCCCTT	TTTCTTTTCTGTTGGCTTGACTTGA	CHP2_BRAF_1
BRAF	chr7	CCACAAATGGATCCAGACAACCTGT	GCTTGCTCTGATAGGAAAATGAGATCTA	CHP2_BRAF_2
CDKN2A	chr9	CACCAGCGTGTCCAGGAA	CCCTGGCTCTGACCATTCTGT	CHP2_CDKN2A_1
CDKN2A	chr9	CATCTATGCGGGCATGGTACT	CGCTGGTGGTGTCTG	CHP2_CDKN2A_2
CTNNB1	chr3	ACTGTTTCGTATTTATAGCTGATTTGATGGA	CCTCTTCTCAGGATTGCCTTT	CHP2_CTNNB1_1
EGFR	chr7	CCTCATTGCCCTCAACACAGT	TCAGTCCGGTTTTATTGTCATCATAGTT	CHP2_EGFR_1
EGFR	chr7	CACCAGTACCAGATGGATGT	CCCAAAGACTCTCCAAGATGGGATA	CHP2_EGFR_2
EGFR	chr7	AGACATGCATGAACATTTTTCTCCAC	TCCAGACCAGGGTGTGTTTTTC	CHP2_EGFR_3
EGFR	chr7	TGTGGAGCTCTTACACCCA	GTGCCAGGGACCTTACCTTATAC	CHP2_EGFR_4
EGFR	chr7	ACGTCTTCTCTCTCTGTCA	CTGAGGTTCAGAGCCATGGA	CHP2_EGFR_5
EGFR	chr7	CATGCGAAGCCACACTGAC	ACATAGTCCAGGAGGCA	CHP2_EGFR_6
EGFR	chr7	GACTATGTCCGGGAACACAAAGA	CCCATGGCAAACCTTGCTA	CHP2_EGFR_7
EGFR	chr7	CGCAGCATGTCAAGATCACAGAT	GCATGTGTTAAACAATACAGCTAGTG	CHP2_EGFR_8
FBXW7	chr4	TGACAATGTTTAAAGTGGTAGCTGTT	ACTCATTGATAGTTGGAACCAACACA	CHP2_FBXW7_1
FBXW7	chr4	CCTGTGACTGCTGACCAAACCTTTTA	CACATCTTCTTATAGGTGCTGAAAGG	CHP2_FBXW7_2
FBXW7	chr4	CCCAACCATGACAAGATTTTCCC	GGTCATCACAATGAGAGACAACATCA	CHP2_FBXW7_3
FBXW7	chr4	ACTAACAAACCCTCTGCCATCATA	TCTGCAGAGTTGTTAGCGGTT	CHP2_FBXW7_4
FBXW7	chr4	GTAGAATCTGCATTCCAGAGACAA	TCTCTGATACATCAATCCGTGTTTGG	CHP2_FBXW7_5
FGFR2	chr10	CATCACTGTAACCTTGAGACAAAAC	TGGTCTCTCATTCTCCCATCCC	CHP2_FGFR2_1
FGFR2	chr10	CATCCTCTCTCAACTCCAACAGG	AGTGGATCAAGCACGTGGAAAA	CHP2_FGFR2_2
FGFR2	chr10	GCTTCTTGGTCTGTTCTTCATT	CTCCTCTGTGATCTGCAATCT	CHP2_FGFR2_3
FGFR2	chr10	TGGAAGCCAGCCATTTCTAAA	GATGATGAAGATGATGGGAAACACAAG	CHP2_FGFR2_4
GNAS	chr20	TTGGTGAGATCCATTGACCTCAATTT	TGAATGTCAAGAAACCATGATCTGT	CHP2_GNAS_1
GNAS	chr20	CCTCTGGAATAACAGCTGTCC	TGATCCCTAACAAACACAGAAGCAA	CHP2_GNAS_2

IDH1	chr2	CCAACATGACTTACTTGATCCCCAT	ATCACCAAATGGCACCATACGA	CHP2_IDH1_1
IDH2	chr15	ACCCTGGCCTACCTGGTC	AGTTCAAGCTGAAGAAGATGTGGAA	CHP2_IDH2_1
KRAS	chr12	CAAAGAATGGTCTGCACCAGTAATAT	AGGCCTGCTGAAAATGACTGAATATAA	CHP2_KRAS_1
KRAS	chr12	TCCTCATGTACTGGTCCCTCATT	GTAAAAGGTGCACTGTATAATCCAGACT	CHP2_KRAS_2
KRAS	chr12	CAGACTGTATTTATTTTCAGTGTACTTACCT	GACTCTGAAGATGTACCTATGGTCTTA	CHP2_KRAS_3
NRAS	chr1	CCTCACCTCTATGGTGGGATCATAT	GTTCTTGCTGGTGTGAAATGACTG	CHP2_NRAS_1
NRAS	chr1	TTGCCTGTCTCATGTATTGG	CACCCCAGGATTCTTACAGAAAA	CHP2_NRAS_2
NRAS	chr1	GCACAAATGCTGAAAGCTGTACC	CAAGTGTGATTTGCCAACAAAGGA	CHP2_NRAS_3
PIK3CA	chr3	CCATAAAGCATGAACTATTTAAAGAAGCAAGA	GGTTGAAAAAGCCGAAGGTCAC	CHP2_PIK3CA_1
PIK3CA	chr3	TGGAATGCCAGAACTACAATCTTTTGAT	AAGATCCAATCCATTTTGTGTGC	CHP2_PIK3CA_10
PIK3CA	chr3	TGGATCTCCACACAATTAACAGCAT	TGCTGTTCATGGATTGTCAATTC	CHP2_PIK3CA_11
PIK3CA	chr3	CCCTTTTTAAAGTAATTGAACCAAGTAGGC	TTTAAGATTACGAAGGATTGGTTAGACAGAA	CHP2_PIK3CA_2
PIK3CA	chr3	GACGCATTTCCACAGCTACAC	AGCATCAGCATTTGACTTTACCTTATCA	CHP2_PIK3CA_3
PIK3CA	chr3	CATAGGTGGAATGAATGGCTGAATTATG	TCAATCAGCGGTATAATCAGGAGTTTTT	CHP2_PIK3CA_4
PIK3CA	chr3	TCCCATTATTATAGAGATGATTGTTGAATTTTCT	CAAAACAAGTTTATATTTCCCATGCCA	CHP2_PIK3CA_5
PIK3CA	chr3	GCTTTGAATCTTTGGCCAGTACCT	CATAAGAGAGAAGGTTTGACTGCCATA	CHP2_PIK3CA_6
PIK3CA	chr3	CAGAGTAACAGACTAGCTAGAGACAATGA	GCACTTACCTGTGACTCCATAGAAA	CHP2_PIK3CA_7
PIK3CA	chr3	CACGATTCTTTAGATCTGAGATGCACA	CCTTTGTGTTTCATCCTTCTCTCTG	CHP2_PIK3CA_8
PIK3CA	chr3	GATGCAGCCATTGACCTGTTTAC	AGAAAACCATTACTTGTCCATCGTCT	CHP2_PIK3CA_9
PTEN	chr10	GCCATCTCTCTCCTCTTTTCTT	GCCGCAGAAATGGATACAGGTC	CHP2_PTEN_1
PTEN	chr10	TGTTAATGGTGGCTTTTGTGTTGTTGT	TCTACCTCACTCTAACAAAGCAGATAACT	CHP2_PTEN_2
PTEN	chr10	CCATAACCCACACAGCTAGAA	TGCCCGATGTAATAAATATGCACAT	CHP2_PTEN_3
PTEN	chr10	GGCTACGACCCAGTTACCATAG	TGCCACTGGTCTATAATCCAGATGAT	CHP2_PTEN_4
PTEN	chr10	TGAGATCAAGATTGCAGATACAGAATCC	ACCTTTAGCTGGCAGACCAC	CHP2_PTEN_5
PTEN	chr10	AGGTGAAGATATATTCTCCAATTCAGGAC	TTGGATATTTCTCCAATGAAAGTAAAGTAC	CHP2_PTEN_6
PTEN	chr10	CACTTTTGGGTAATACATTCTCATACCAGGA	TATACTGCAAATGCTATCGA	CHP2_PTEN_7
PTEN	chr10	GCAGTATAGAGCGTGCAGATAATGA	CATCACATACACAAGTCAACAACCC	CHP2_PTEN_8
RNF43	chr17	CCAAACACATCTGGAGCACACT	GCCTGACCCTCAATGACCTCTT	RNF43_1.100174
RNF43	chr17	CCGCTTTTGTAGTGGTGGT	TGACTTTGACCCCTAGTGTACT	RNF43_2.1.213215
RNF43	chr17	ACAACCACTGGCTGTGAA	GCACCCAGCTTCCAGATT	RNF43_2.1.22754
RNF43	chr17	CGGTGTCAGAATCCATTAGAAAG	GACAAGAGGCTGCTACCAGAAA	RNF43_2.1.264668
RNF43	chr17	CTCTCCCTACCACCCACTT	GTGGTTGTGCCTGACTCCTC	RNF43_2.1.277654
RNF43	chr17	CTGGGTGCACAGTTGCATC	CCCTGGCCAGTTGACG	RNF43_2.1.308947
RNF43	chr17	GAAACCTGGGTTTCCCTGT	GGGTCCATGGCAGCAGTTC	RNF43_2.1.342797
RNF43	chr17	AAAGTCACTGCTTAGGGAGCT	AGAAAGCTATTGCACAGAACGC	RNF43_2.1.4249
RNF43	chr17	GGGACCAAGGATATGCCACACT	TGCAAAAATCCAGCCTCTCTGC	RNF43_2.1.479773
RNF43	chr17	GGGCACTGTGGTTAGAGAG	AAAAGCGGTTCCAGTGGCA	RNF43_2.1.483268
RNF43	chr17	GTGACTTGCTGATCAGGAGAAGGT	GTTTCCAGCCATGTCCACTACC	RNF43_2.1.554471
RNF43	chr17	TTTTTGCAAGTTGAACAGACTGCT	CAAGTACCAGATCCAATCAGC	RNF43_2.1.716452
RNF43	chr17	CTCCAGATCCACTGCTGTCA	TTCCCCAGAGCTGCACATC	RNF43_2.2.168519
RNF43	chr17	GTAGGCTGATGTCCGTGCAG	GCTTGCCAGTGCCCTTA	RNF43_2.2.335644
RNF43	chr17	GTGCTGTGAGGTGGATTGGAG	CCCACGACCTGGTCCCTT	RNF43_2.2.348341
RNF43	chr17	GTGATGCCGAGGGCCCAT	CAGGTGCAAGACTCCACCTC	RNF43_2.2.359855
RNF43	chr17	AGGTGGTAGTGGGATGGC	TGTCTTCTGAATGCATTCTGTAGG	RNF43_2.2.62203
RNF43	chr17	CCTCTACTGTGATGTTGAACATG	CCTGATTCTGGCAATCCTATGG	RNF43_3.144168

RNF43	chr17	AAGCCACATTCTAGACCTGTCTG	CTCTTTTTCTCCAGGACTACGG	RNF43_3.9926
RNF43	chr17	TCCTCCAGACAGATGGCACA	CCCAATCTGAGCCCCATTCT	RNF43_4.332752
RNF43	chr17	TTCAATCTCCCCAGTCTGGTCAT	AGCTGGCCACCAGGAGGTA	RNF43_4.381754
RNF43	chr17	TACTCCTTCTTCTCCCTAACCCAC	ATGATGTGTGGATCCTAATGACAGT	RNF43_5.252108
RNF43	chr17	AAGCCAGGATGATCACAAGATGG	CTCAAGGGAACCTCCAGTTAGCTAT	RNF43_5.9080
RNF43	chr17	CCCTGAGAGCTTTATCTTCTCCATC	GACCTCAGCCCAACCTCTACT	RNF43_6.126819
RNF43	chr17	GTCTGGAGGTCTAGTGTGCT	TGGGCACCTTCCCCCTGTA	RNF43_6.251138
RNF43	chr17	ATCAGCTTCTCAGCGTCATTACC	CTGGATGGAGGAAGATAAAGCTCTCA	RNF43_6.62210
RNF43	chr17	CACAGGACAAAGTAGGGCTAAGTG	AAGCTGATGGAGTTTGTGTACAAGAA	RNF43_6.83735
RNF43	chr17	CCAGCTTGACGATGCTGATGAAT	TGGTACTCTCCCTAGAAAATGGAGAG	RNF43_8.145848
RNF43	chr17	GTGTAGGGCGAAGTGTGAGTC	CCTAACCCAAGTCTGTCTCTCTG	RNF43_8.334246
RNF43	chr17	ATTTCCACTTCTCTCAGACCAAGTCAT	CCTGTCACTGGCTAGCAAGGTA	RNF43_8.99948
RNF43	chr17	GCAAACACACCTTCCAAAGTGAGATT	TGGACGCACAGGACTGGTAC	RNF43_9.251835
RNF43	chr17	ACAAAAGAAGAAAGACATATTTCAAACAGATG	TTATCAGAGTGATCCCTTGAAAATGG	RNF43_9.43347
RNF43	chr17	AGCTTTCTGTCTGCTGATCTTCA	GTATGTATGGTTGAAGTGCATTGCTG	RNF43_9.83487
SMAD4	chr18	CTCATGTGATCTATGCCGCTCT	AGTCTACTTACCAATCCAGGTGATACA	CHP2_SMAD4_1
SMAD4	chr18	TGCTACTTCTGAATTGAAATGGTTCA	GATTACTACCATTACTCTGCAGTGTT	CHP2_SMAD4_2
SMAD4	chr18	ATGGTGAAGGATGAATATGTGCATGA	GCTGGTAGCATTAGACTCAGATGG	CHP2_SMAD4_3
SMAD4	chr18	GTGAAGGACTGTTGCAGATAGCAT	AAGGCCACATGGGTTAATTTG	CHP2_SMAD4_4
SMAD4	chr18	TTTCTTTAGGGCTTTCACAATGA	CTGAGAAGTGACCCATAATCCATT	CHP2_SMAD4_5
SMAD4	chr18	GCTCCTGAGTATTGGTGTCCAT	CCTGTGGACATTGGAGAGTTGA	CHP2_SMAD4_6
SMAD4	chr18	TGTAATTTCTTTTTCTTCTAAGGTTGCACATAG	ACTTGGGTAGATCTTATGAACAGCAT	CHP2_SMAD4_7
SMAD4	chr18	AGGCTTTTGATTGCGTCAGTGT	GCTGGAGCTATCCACTACTG	CHP2_SMAD4_8
SMAD4	chr18	GCTGCTGGAATTGGTGTGATG	AGTACTCGTCTAGGAGCTGGAG	CHP2_SMAD4_9
STK11	chr19	GAGCTGATGTCGGTGGGTAT	CTCCGAGTCCAGCACCTC	CHP2_STK11_1
STK11	chr19	CTCCAGGCAGCTGCAA	CCGGTGGTGAGCAGCAG	CHP2_STK11_2
STK11	chr19	CCGGTGGCACCTCAA	CTGGTCCGGCAGGTGTC	CHP2_STK11_3
STK11	chr19	AACATCACACGGGTCTGTAC	GATGAGGCTCCACCTTCAG	CHP2_STK11_4
STK11	chr19	GAAGAAACATCCTCCGGCTGAA	ACCGTGAAGTCTGAGTGTAGA	CHP2_STK11_5
TP53	chr17	TCCACTCACAGTTTCCATAGGTCT	GTTGGAAGTGTCTCATGCTGGAT	CHP2_TP53_1
TP53	chr17	GGCTGTCCAGAATGCAAGAA	GATGAAGCTCCAGAATGCCA	CHP2_TP53_2
TP53	chr17	TGCACAGGGCAGGTCTTG	CCGTCTCCAGTTGCTTTATCTGT	CHP2_TP53_3
TP53	chr17	ACCAGCCTGTCTCTCT	GTGCAGCTGTGGTTGATTC	CHP2_TP53_4
TP53	chr17	CCAGTTGCAAACAGACCTCA	AGGCCTCTGATTCCTCACTGAT	CHP2_TP53_5
TP53	chr17	GGCTCCTGACCTGGAGTCTT	CTCATCTTGGGCTGTGTTATCTC	CHP2_TP53_6
TP53	chr17	CGCTTCTGTCTGCTTCT	TTCTTTTTCTATCTGAGTAGTGGT	CHP2_TP53_7
TP53	chr17	GGAAGGGGCTGAGGTCACT	CCCCTCTCTGTTGCTGC	CHP2_TP53_8
VHL	chr3	CTCCAGGTCATCTTCTGCAAT	GTACCTCGGTAGCTGTGGATG	CHP2_VHL_1
VHL	chr3	GTGGCTCTTAAACCTTTGCT	GTCAGTACCTGGCAGTGTGATA	CHP2_VHL_2
VHL	chr3	GGCAAAGCCTCTTGTCTGTTTC	TGACGATGTCCAGTCTCTGTAAT	CHP2_VHL_3

1

1 **Supplementary table 3: Mutation profile of precursor lesions detected by targeted NGS.**

Grade	Gene	Sample	Variant	VAF [%]	Variant Effect	Transcript
low-grade PanIN	<i>ARID1A</i>	113	Gln802fs	4.83	frameshift/insertion	NM_006015.5
	<i>CDKN2A</i>	74	Arg58Ter	3.48	nonsense	NM_001195132.1
	<i>GNAS</i>	127	Arg201His	20.17	missense	NM_000516.5
	<i>KRAS</i>	52	Gly12Val	15.38	missense	NM_033360.3
		55	Gly12Val	9.66	missense	NM_033360.3
		56	Gly12Asp	6.13	missense	NM_033360.3
		69	Gln61His	4.08	missense	NM_033360.3
		74	Gly12Asp	12.05	missense	NM_033360.3
		111	Gly12Val	11.19	missense	NM_033360.3
		125	Gly12Val	4.29	missense	NM_033360.3
		127	Gly12Asp	18.24	missense	NM_033360.3
		128	Gly12Asp	3.42	missense	NM_033360.3
		129	Gly12Asp	3.7	missense	NM_033360.3
		113	Gly12Arg	4.18	missense	NM_033360.3
	113	Gly12Val	8.75	missense	NM_033360.3	
	43	Gly12Val	12.88	missense	NM_033360.3	
	<i>PIK3CA</i>	68	Arg349Ter	3.74	nonsense	NM_006218.3
127		Phe83fs	4.52	frameshift/deletion	NM_006218.3	
<i>PTEN</i>		128	Asn323fs	22.37	frameshift/deletion	NM_000314.6
high-grade PanIN	<i>ARID1A</i>	73	Trp2091Ter	7.46	nonsense	NM_006015.4
	<i>GNAS</i>	96	Arg201His	3.42	missense	NM_000516.5
	<i>KRAS</i>	73	Gly12Asp	8.29	missense	NM_033360.3
		80	Gly12Val	16.59	missense	NM_033360.3
		101	Gly12Asp	13.7	missense	NM_033360.3
		104	Gly12Asp	5.15	missense	NM_033360.3
		114	Gly12Val	18.3	missense	NM_033360.3

	<i>TP53</i>	80	Arg213Ter	34.5	nonsense	NM_000546.5
		104	Arg196Ter	4.04	nonsense	NM_000546.5
low-grade IPMN gastric	<i>ARID1A</i>	21	Asp1850fs	7.45	frameshift/insertion	NM_006015.5
	<i>GNAS</i>	2	Arg201His	33.98	missense	NM_000516.5
		7	Arg201Cys	11.34	missense	NM_000516.5
		35	Arg201His	41.52	missense	NM_000516.5
		62	Arg201Cys	15.56	missense	NM_000516.5
		86	Arg201His	30.46	missense	NM_000516.5
		89	Arg201His	5.56	missense	NM_000516.5
		94	Arg201His	21.97	missense	NM_000516.5
		97	Arg201Cys	33.81	missense	NM_000516.5
		99	Arg201His	25.08	missense	NM_000516.5
		110	Arg201Cys	22.37	missense	NM_000516.5
		112	Arg201His	24.32	missense	NM_000516.5
		54	Arg201Cys	23.16	missense	NM_000516.5
	<i>KRAS</i>	21	Gly12Val	18.86	missense	NM_033360.3
		2	Gly12Val	35.1	missense	NM_033360.3
		7	Gly12Val	12.14	missense	NM_033360.3
		35	Gly12Asp	38.57	missense	NM_033360.3
		39	Gly12Val	35	missense	NM_033360.3
		61	Gly12Val	18.03	missense	NM_033360.3
		62	Gly12Val	18.5	missense	NM_033360.3
		64	Gly12Val	9.01	missense	NM_033360.3
		86	Gly12Val	27.81	missense	NM_033360.3
		89	Gln61His	36.49	missense	NM_033360.3
		94	Gly12Asp	21.16	missense	NM_033360.3
		97	Gly12Asp	33.68	missense	NM_033360.3

		99	Gly12Val	26.83	missense	NM_033360.3
		110	Gly12Val	24.76	missense	NM_033360.3
		57	Gly12Arg	6.96	missense	NM_033360.3
	<i>STK11</i>	61	Tyr60Ter	61.89	nonsense	NM_000455.4
high-grade IPMN gastric	<i>ARID1A</i>	130	Gln2115Ter	30.84	nonsense	NM_006015.5
	<i>GNAS</i>	51	Arg201Cys	31.03	missense	NM_000516.5
	<i>KRAS</i>	51	Gly12Val	33.12	missense	NM_033360.3
		65	Gly12Asp	16.51	missense	NM_033360.3
		66	Gly12Asp	33.64	missense	NM_033360.3
		130	Gly12Asp	22.65	missense	NM_033360.3
		131	Gly12Asp	23.98	missense	NM_033360.3
	<i>TP53</i>	65	Arg248Trp	17.99	missense	NM_000546.5
low-grade IPMN intestinal	<i>GNAS</i>	92	Arg201Cys	80.59	missense	NM_000516.5
	<i>KRAS</i>	92	Gly12Arg	37.95	missense	NM_033360.3
high-grade IPMN intestinal	<i>GNAS</i>	33	Arg201Cys	45.42	missense	NM_000516.5
		88	Arg201Cys	36.81	missense	NM_000516.5
		90	Arg201His	35.51	missense	NM_000516.5
		17	Gln227Lys	42.36	missense	NM_000516.5
	<i>KRAS</i>	88	Gly12Ser	33.81	missense	NM_033360.3
	<i>TP53</i>	88	Met237Thr	49.16	missense	NM_000546.5

1 PanIN/IPMN in cases without associated/concomitant PDAC are indicated in bold.

2

3

4

5

1 **Supplementary table 4. Distribution of CNV-positive and negative precursor lesions**
2 **according to the degree of dysplasia.**

		<i>CNV pos</i>	<i>CNV neg</i>
<i>PanIN</i>	Low-grade	16 (57%)	12 (43%)
	High-grade	6 (75%)	2 (25%)
<i>Gastric IPMN</i>	Low-grade	22 (76%)	7 (24%)
	High-grade	6 (75%)	3 (25%)
<i>Intestinal IPMN</i>	Low-grade	8 (100%)	0
	High-grade	13 (100%)	0

3 Percentages refers to the total number of cases in each group

4

5

6

7

8

9

10

11

12

13

14

Supplementary table 5: Overview of log₂ copy number ratios sorted in ascending order. Values of genomic alterations were detected by low-coverage sequencing (n=28) and DNA methylation data (n=67), respectively.

Genomic location	affected samples (n)	PanIN (n=36)	gIPMN (n=38)			iIPMN (n=21)		
deleted regions								
chr01:010875000-013052998	3					-0.26	-0.25	-0.24
chr01:015375000-016825000	3					-0.26	-0.25	-0.20
chr06:074175000-074375000	5		-0.29	-0.22	-0.21	-0.44	-0.24	
chr06:133664400-143100000	5		-0.37	-0.28		-0.50	-0.45	-0.28
chr06:143620678-151100000	7	-0.21	-0.37	-0.34	-0.29	-0.50	-0.45	-0.28
chr09:005958053-023802212	5	-0.23	-0.51	-0.36	-0.36	-0.24		
chr10:071075000-120925000	6		-0.45	-0.22		-0.36	-0.30	-0.28
chr10:120925000-125869472	5		-0.30			-0.41	-0.30	-0.28
chr11:057325000-058807232	4					-0.44	-0.40	-0.27
chr11:058807232-069089801	5					-0.44	-0.40	-0.28
chr11:096437584-114325000	5					-0.51	-0.44	-0.40
chr11:114325000-134898258	4					-0.51	-0.44	-0.28
chr17:006225000-009675000	4		-0.50	-0.32	-0.21	-0.23		
chr17:009675000-012500000	5		-0.53	-0.31	-0.21	-0.50	-0.22	
chr17:015792977-021566608	6		-0.58	-0.23	-0.21	-0.49	-0.32	-0.25
amplified regions								
chr01:035225000-037325000	3					0.25	0.33	0.61

chr03:176225000-188875000	6	0.26	0.21	0.23	0.28	0.38	0.44				
chr05:028950000-044925000	5				0.24	0.25	0.31	0.74	0.79		
chr06:024125000-033575000	5		0.25	0.36	0.31	0.35	0.56				
chr06:033575000-042725000	4		0.42		0.32	0.34	0.56				
chr07:000282484-007150000	5				0.22	0.30	0.32	0.36	0.41		
chr07:054725000-055775000	5				0.21	0.26	0.27	0.33	0.36		
chr07:061967157-074715724	4				0.27	0.32	0.36	0.37			
chr07:112425436-130154523	5				0.21	0.33	0.36	0.38	0.57		
chr07:139404377-142048195	5				0.22	0.32	0.36	0.33	0.58		
chr07:143397897-154270634	5				0.24	0.33	0.34	0.38	0.59		
chr08:086726451-089550000	3				0.21	0.31	0.36				
chr08:127450000-129175000	7	0.42			0.21	0.27	0.29	0.36	0.56	0.66	
chr09:001992685-035698318	3				0.24	0.32	0.61				
chr09:070835468-092343416	4				0.22	0.26	0.32	0.60			
chr09:096718222-097575000	4				0.21	0.24	0.32	0.60			
chr09:097775000-114750000	4				0.22	0.26	0.32	0.61			
chr09:124994207-133073060	3				0.22	0.32	0.61				
chr12:006475000-007169938	8	0.21			0.24	0.33	0.56	0.71	0.88	0.89	1.70
chr12:024993545-028938805	4	0.21			0.21	0.38	1.32				
chr14:020700000-022050000	3				0.21	0.28	0.33				
chr14:022800000-050175000	3				0.22	0.25	0.35				
chr14:097258910-107289540	3				0.25	0.22	0.36				
chr17:061125000-062410760	3				0.32	0.32	0.74				
chr17:062775000-063525000	3				0.32	0.34	0.49				
chr17:068117898-077546461	3				0.21	0.32	0.38				

chr20:008050000-016400000	7	0.24	0.22	0.23	0.24	0.26	0.33	0.84
chr20:016625000-021300000	7	0.25	0.22	0.23	0.25	0.28	0.33	0.82
chr20:030025000-034897085	7	0.26	0.22	0.22	0.23	0.31	0.33	0.81
chr20:036958189-042991501	6	0.26	0.22	0.23	0.35	0.33	0.79	
chr20:052650000-061091437	7	0.23	0.22	0.22	0.23	0.33	0.35	0.80
chr21:032825000-034475000	3		0.21	0.26	0.30			

1

1 **Supplementary table 6a: Differentially methylated probes in low- and high-grade pancreatic**
 2 **cancer precursors.**

	Low-grade samples	High-grade samples	DMPs (hypermethylated in high-grade)	DMP associated genes (hypermethylated in high-grade)
iPMN	8	12	0	0
gIPMN	24	8	0	0
PanIN	20	7	86 (62)	59 (45)

3 iPMN: intestinal IPMN; gIPMN: gastric IPMN

4

5 **Supplementary table 6b: Genes associated with significantly hyper- or hypomethylated CpG**
 6 **in PanIN high-grade**

Genes associated with at least one significantly hypermethylated CpG	Genes associated with at least one significantly hypomethylated
TAC1	GLRX
AKAP13	BCL11B
POLR1D	ITFG3
GLYATL3	IFT140
HOXA5	CTNNA3
ZIC2	RUNX1
SIM2	SPARCL1
ARID4B	PHLDB1
MON2	NINJ2
CNKSR3	METTL9
SP8	SLC51A
ADD2	EMID2
HOXB1	CACNA1A
ST3GAL6	C19orf35
FBN2	
ZIK1	
LRP1B	
NTRK3	
GLI3	
NTM	
RASGRF1	
FAM46C	

NXPH1	
LBX2	
LOC101929710	
ADRA1A	
GRIK3	
PARP8	
KIAA1026	
SLC6A15	
IRX1	
GRIA4	
TLE4	
DGKI	
PACSIN2	
DOK5	
ZIC4	
MYLK	
DAPK1	
C5orf66-AS1	
AMER3	
CPEB1	
ST6GAL2	
INA	
AP2A2	

1

1 **Supplementary Figure Legends**

2 **Supplementary figure 1: Overview of lesions and methods**

3 55 PanINs, 46 gastric IPMNs (gIPMN) and 21 intestinal IPMNs (iIPMN) were subjected to 4
4 main analyses: targeted next generation sequencing (n=52), low-coverage whole-genome
5 sequencing (n=28), genome-wide DNA methylation analysis (n=79) and transcriptome analysis
6 (n=34). Each circle of the diagram represents one of the mentioned methods and includes the
7 number of samples used for related analyses. The samples that could not be placed into the
8 diagram were shown at the right bottom corner of the figure. Pancreatobiliary and mixed-type
9 IPMNs were excluded from further analyses due to small sample size.

10 **Supplementary figure 2: Allele frequency of *KRAS* and *GNAS* mutations in different precursor 11 lesions.**

12 (A) VAF of *KRAS* mutations; (B) VAF of *GNAS* mutations; (C) scatterplot of the VAF of the *KRAS*
13 mutations (G12) against the VAF of *GNAS* mutations (R201) detected in low- and high-grade
14 gastric IPMN. The grey lines represent the 95% confidence interval of the Pearson's correlation
15 coefficient r (n=9). (Kruskal-Wallis-test * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$).

16

17 **Supplementary figure 3: Morphology of lesions with different genetic status according to 18 targeted NGS**

19 Representative HE images of low- and high-grade PanINs, gastric IPMNs and intestinal IPMNs
20 with variable mutation profiles detected by targeted NGS are shown. No specific morphology
21 was identified related to the mutation status between the samples in the same diagnostic
22 group. In particular, gastric lesions with *GNAS* mutations (case 127, 96, 99 and 112) did not
23 show relevant intestinal differentiation; only in case 112, focal (<5% of the cells) expression of
24 *MUC2* and *CDX2* was observed (not shown). Scale bars represent 200 μm . Detailed mutation
25 profile of the samples is provided in Suppl. Table 3.

26 **Supplementary figure 4: Quality control of DNA methylation data derived from normal 27 pancreas cell preparations.**

28 (A) Multi-dimensional scaling of the 1000 most variable probes. (B) Hierarchical clustering of
29 probes for known acinar and ductal marker genes.

1

2 **Supplementary figure 5: Proliferation activity, expression of TFF3 and of MUCL3 protein in**
3 **PanIN, IPMN and PDAC.**

4 Representative images (A) and related graphs (B-D) of IHC staining performed in whole tissue
5 sections in 31 PanIN, 28 gastric IPMN, 20 intestinal IPMN and 24 PDAC. Intestinal IPMNs and
6 PDACs showed higher proliferation rates with Ki67 staining than PanIN and gastric IPMN. TFF3
7 was strongly expressed in intestinal IPMN. Gastric IPMN revealed higher expression of MUCL3
8 compared to PanIN. Scale bars represent 100 μ m. (IRS: immunoreactivity score) (* p <0.05).

9

10 **Supplementary figure 6: Hierarchical clustering of DNA methylation data based on published**
11 **marker genes for distinct normal pancreas cell populations.** The mean methylation beta-
12 value for all gene associated probes is displayed, respectively.

13

14 **Supplementary figure 7: Differentially activated gene sets.** Displayed pathways were
15 detected by pairwise comparison between the indicated lesions. Odds ratios below 0.8
16 indicate the activation in the first listed lesion whereas 1.1 is associated with the second
17 group. The analyzed gene sets based on the KEGG pathway (A) and hallmarks (B) from
18 the MSigDB.

19

20

21

22

23